Praxis precision medicines to present analyses of patient-focused, clinically meaningful endpoints from essential1 study of ulixacaltamide in essential tremor at the 2023 mds international congress

Boston, aug. 28, 2023 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting analyses highlighting patient-focused endpoints from its essential1 study of ulixacaltamide (prax-944) in essential tremor (et) at the international parkinson and movement disorder society's (mds) international congress of parkinson's disease and movement disorders®, taking place in copenhagen, denmark.
PRAX Ratings Summary
PRAX Quant Ranking